Much as it happened with CML, targeted therapies are challenging the role of allogeneic hematopoietic cell transplantation (alloHCT) in the treatment of CLL. Despite alloHCT being the only curative therapy for CLL, its broad implementation is limited by significant toxicity, a long-term procedure-related mortality of around 15-25%, the availability of a fully-matched donor and the advanced age of most patients with the disease. As a result, and not surprisingly, around 30% of patients with CLL in whom allogeneic stem cell transplantation is considered as a treatment possibility are not eventually transplanted. 1 In contrast, targeted therapies such as B-cell receptor inhibitors (BCRi) (ibrutinib, idelalisib) or B-cell lymphoma 2 (BCL2) antagonists (venetoclax), albeit not curative, can be given to a wide range of patients and provide results comparable to those of alloHCT with much lower toxicity. 2 Of note, treatment results with BCRi and BCL2 antagonists are likely to improve by combining these agents among themselves and/or with monoclonal antibodies. 2, 3 Those facts led investigators from the European Society for Bone Marrow Transplantation (EBMT) and the European Research Initiative on CLL to refine EBMT prior recommendations and to restrict alloHCT to selected patients previously treated with one of these agents. 4 The question we face now is: should targeted therapies replace alloHCT entirely?
Ample evidence shows that alloHCT is able to eradicate (cure) the disease, even in the presence of poor prognostic features (for example, TP53 disruption), although it works best when the disease is under control. 5 Even with reduced-intensity conditioning regimes (which have replaced fully mieloblative conditioning in CLL allotransplantation) toxicity is considerable, mostly due to GvHD and infections, although it tends to decrease over time, and disease relapse is rare 4 years after transplantation. In turn, targeted therapies achieve remarkable and sustained responses, but hardly ever eradicate the disease. Of note, patients with TP53 disruption receiving these agents have an inferior long-term outcome compared with patients devoid of this genomic aberration. 6 Survival curves of patients on these agents do not show a plateau, whereas the incidence of class-specific toxic effects (for example, hypertension and atrial fibrillation for ibrutinib; colitis, transaminitis and pneumonitis for idelalisib) apparently remains constant over time. Importantly, a longer follow-up of patients treated with targeted therapies is needed to better define, based on solid ground, the position of these agents in CLL treatment algorithms.
Recent data, however, reinforce the notion that alloHCT and targeted therapies should be regarded as complementary rather than antagonistic strategies. 7, 8 In this issue of Bone Marrow Transplantation, Link et al. 9 provide further evidence of the beneficial role of ibrutinib in this context. In this study, five patients with extensively pre-treated high-risk CLL received ibrutinib for progressive CLL at a median of 28 months after alloHCT. Remarkably, all patients responded to therapy and four of them remained in remission at last follow-up. The drug was generally well tolerated and the only death was observed in a patient who developed pneumonia, which may or may not have been drug related. As a bonus, in one patient with active GvHD at the time of treatment initiation, GvHD improved upon ibrutinib administration, and the drug did not trigger GvHD in any of the four remaining patients. This report adds to the still scanty evidence about the role of targeted therapies in patients with relapsed CLL after alloHCT. Rozovski et al. 10 analyzed the outcome of 52 patients who relapsed after alloHCT. Five of these patients received ibrutinib, and four of them responded to therapy and were disease free 16 months after treatment initiation. 10 In another series of 16 patients, reported in abstract form, a 87.5% response rate and a 77% PFS at 2 years for patients receiving ibrutinib for relapsed disease post alloHCT have been reported. 11 Finally, the role of ibrutinib as therapy for GvHD warrants further investigation. In this regard, preclinical studies have already proved that in murine models of chronic GvHD, ibrutinib delays progression, improves survival and ameliorates the clinical and pathological manifestations of GvHD. 12 Altogether, despite the paucity of data, targeted therapies hold much promise as potential tools to improve the results of alloHCT by (1) debulking the disease before transplantation, (2) preventing/treating GvHD; and (3) treating relapse/progression after transplantation. But each one of these potential advantages needs careful evaluation in well-designed studies. Ultimately, only a clever combination of current and future therapeutic strategies will lead to a better outcome for patients with high-risk CLL.
